Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) attributable loss narrowed to 1.28 billion yuan in 2024 from 2.28 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the drug company fell to 1.30 yuan from 2.32 yuan in the previous year.
Total operating income grew 30% to 1.94 billion yuan from 1.50 billion yuan a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。